The expression level and clinical significance of C-reactive protein in full-term newborns with ABO hemolytic disease
Objective To investigate the expression level and clinical significance of C-reactive protein(CRP)in full-term newborns with ABO hemolytic disease.Methods The full-term newborns with hyperbil-irubinemia who were hospitalized in the neonatal care center from January 2020 to December 2022 were retro-spectively included as the research objects.They were divided into the ABO hemolytic group and the non-he-molytic hyperbilirubinemia group(the non-hemolytic group).The clinical data,CRP values,CRP abnormal rate,and the use of antibiotics were compared between the two groups.Results A total of 662 cases were in-cluded,including 350 cases in the hemolytic group and 312 cases in the non-hemolytic group.The average age of admission and the value of percutaneous jaundice at admission in the hemolytic group were significantly lower than those in the non-hemolytic group(P＜0.05).The average hospitalization time,CRP level on ad-mission and the abnormal detection rate of CRP in the hemolytic group were higher than those in the non-he-molytic group,and the differences were statistically significant(P＜0.05).The abnormal CRP level in the hemolytic group was 15.06(11.81,22.20)mg/L.The utilization rate of antibiotics in the hemolytic group(11.1％)was higher than that in the non-hemolytic group(4.2％),and the difference was statistically signifi-cant(P＜0.05).In the hemolytic group,the average time for the increased CRP to drop to the normal level was 23.00(19.75,36.75)h.Conclusion The expression level of CRP is transiently increased in full-term neo-nates with ABO hemolysis disease,and the average time required to return to normal is about 23 hours.It is not recommended to actively use antibiotics in hemolytic children with elevated CRP levels.It should be dy-namically monitored and combined with multiple inflammatory indicators and clinical manifestations to make decisions on whether to make comprehensive decisions.
万方数据
维普
